Literature DB >> 15560527

Correlation of immunochemical detection of HPV L1 capsid protein in pap smears with regression of high-risk HPV positive mild/moderate dysplasia.

Henrik Griesser1, Heinz Sander, Ralf Hilfrich, Bettina Moser, Ulrich Schenck.   

Abstract

OBJECTIVE: To immunostain Pap smears of high-risk (hr) HPV DNA-positive early squamous lesions for detecting HPV L1 protein. STUDY
DESIGN: Routinely stained archival slides from 84 mild and moderate hrHPV DNA-positive dysplasias were immunostained using a panreactive HPV L1 antibody. Follow-up smears were taken from women with remission for a mean period of 22.8 months (range, 6-46). Conization was done in patients with persistence or progression (3 and 48 patients, respectively) after a mean time of 12 months (range, 9-48).
RESULTS: Twenty-nine of 84 smears (34.5%) had positively stained squamous epithelial cell nuclei. In 9 of 29 (31%) women progressive disease occurred (2 cervical intraepithelial neoplasia [CIN] 2 and 7 CIN 3 lesions on conization) 20 (69%) had remission. Of the 55 L1-negative cases, 13 (23.6%) had remission, 42 (76.4%) progressed (3 CIN 2, 38 CIN 3, 1 microinvasive carcinoma). The difference in follow-up between L1 positive and negative cases was statistically significant (chi2 test, p< or =0.001).
CONCLUSION: Low and moderate dysplastic squamous lesions without immunochemically detectable HPV L1 protein are significantly more likely to progress than are L1-positive cases. Immunochemical L1 capsid detection in routine Pap smears thus offers prognostic information about early dysplastic lesions.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15560527

Source DB:  PubMed          Journal:  Anal Quant Cytol Histol        ISSN: 0884-6812            Impact factor:   0.302


  9 in total

Review 1.  [Who performs gynecological cytology and how?].

Authors:  D Schmidt; H H Neumann
Journal:  Pathologe       Date:  2015-11       Impact factor: 1.011

Review 2.  [Precancerous lesions of the cervix. Biomarkers in cytological diagnosis].

Authors:  D Schmidt
Journal:  Pathologe       Date:  2011-11       Impact factor: 1.011

3.  HPV L1 capsid protein detection and progression of anal squamous neoplasia.

Authors:  Jonathan Hernandez; Abul Elahi; Erin Siegel; Domenico Coppola; Bridgett Riggs; David Shibata
Journal:  Am J Clin Pathol       Date:  2011-03       Impact factor: 2.493

4.  Early detection of cervical carcinomas: finding an overall approach.

Authors:  Nicolas Wentzensen; Stefanie J Klug
Journal:  Dtsch Arztebl Int       Date:  2008-09-12       Impact factor: 5.594

5.  Immunohistochemical detection of human papillomavirus capsid proteins L1 and L2 in squamous intraepithelial lesions: potential utility in diagnosis and management.

Authors:  Anna Yemelyanova; Patti E Gravitt; Brigitte M Ronnett; Ann F Rositch; Aleksandra Ogurtsova; Jeffrey Seidman; Richard B S Roden
Journal:  Mod Pathol       Date:  2012-09-21       Impact factor: 7.842

6.  Biomarkers of cervical dysplasia and carcinoma.

Authors:  Sonya J Hwang; Kenneth R Shroyer
Journal:  J Oncol       Date:  2011-10-29       Impact factor: 4.375

7.  Role of protein biomarkers in the detection of high-grade disease in cervical cancer screening programs.

Authors:  Charlotte A Brown; Johnannes Bogers; Shaira Sahebali; Christophe E Depuydt; Frans De Prins; Douglas P Malinowski
Journal:  J Oncol       Date:  2012-02-28       Impact factor: 4.375

8.  Clinicopathological implications of human papilloma virus (HPV) L1 capsid protein immunoreactivity in HPV16-positive cervical cytology.

Authors:  Sung-Jong Lee; Ah-Won Lee; Chang-Suk Kang; Jong-Sup Park; Dong-Choon Park; Eun-Young Ki; Keun-Ho Lee; Joo-Hee Yoon; Soo-Young Hur; Tae-Jung Kim
Journal:  Int J Med Sci       Date:  2013-12-20       Impact factor: 3.738

9.  Immunohistochemistry and Polymerase Chain Reaction for Detection Human Papilloma Virus in Warts: A Comparative Study.

Authors:  Hong Sun Lee; Ji Hyun Lee; Ji Yoon Choo; Hee Jin Byun; Jin Hyun Jun; Jun Young Lee
Journal:  Ann Dermatol       Date:  2016-07-26       Impact factor: 1.444

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.